Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Jul 16, 2023; 11(20): 4852-4864
Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4852
Table 1 Patient basic information
Imaging/pathological featuresTraining group
Validation group
M+ group (n = 40)
M- group (n = 186)
M+ group (n = 17)
M- group (n = 80)
Age56.15 ± 13.5459.01 ± 10.3865.87 ± 9 .3155.98 ± 10.63
Group, n (%)
    BCS19 (47.5)185 (99.5)8 (47.1)78 (97.5)
    Non-BCS21 (52.5)1 (0.5)9 (52.9)2 (2.5)
Molecular subtypes, n (%)
    Luminal A9 (22.5)64 (34.4)1 (6.7)31 (38.8)
    Luminal B_ Her2(-)16 (40.0)70 (37.6)8 (47.1)33 (41.3)
    Luminal B_ Her2(+)5 (12.5)29 (15.6)5 (29.4)9 (11.3)
    HER2_ enriched6 (15.0)6 (3.2)2 (11.8)4 (5.0)
    TNBC4 (10.0)17 (9.1)0 (0.0)3 (3.8)
Tumor size2.5 (1.1-6.0)2.08 (0.50-5.40)2.27 (1.3-5.0)1.95 (0.80-6.70)